                         SEQUENCE LISTING

<110>  The University of Bath
 
<120>  Drug Delivery Enhancement Agents

<130>  P021142WO

<160>  21    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  PHOSPHORYLATION

<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 any negatively charged amino acid residue, for example pTyr,
       Asp or Glu

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa2 is any small hydrophobic amino acid residue, for example Val
       or Ala

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is any positively charged amino acid residue, for example 
       Lys or Arg

<220>
<221>  VARIANT
<222>  (4)..(4)
<223>  Xaa4 is any hydrophillic amino acid residue, for exampleTyr, Phe,
       Thr or Ser

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa4 is anynegatively charged amino acid residue, for example 
       PTyr, Asp or Glu

<400>  1

Tyr Val Lys Tyr Tyr 
1               5   


<210>  2
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa at position 1 is any amino acid residue

<400>  2

Xaa Tyr Gln Tyr 
1               


<210>  3
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide

<400>  3

Arg Arg Val Glu Val Lys Tyr Asp Arg Arg 
1               5                   10  


<210>  4
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide

<400>  4

Arg Lys Ala Lys Tyr Gln Tyr Arg Arg Lys 
1               5                   10  


<210>  5
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa is up to 10 positively charged amino acid residues

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa2 is a positively charged amino acid residues

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is absent or a hydrophobic amino acid residues

<220>
<221>  VARIANT
<222>  (4)..(4)
<223>  Xaa4 is a negatively charged amino acid residues

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is a small hydrophobic amino acid residues

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa6 is a positively charged amino acid residues

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is a hydrophobic amino acid residues

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  Xaa8 is a negatively charged amino acid residues

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  Xaa8 is a negatively charged amino acid residues

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  Xaa9 is a positively charged amino acid residues

<220>
<221>  VARIANT
<222>  (10)..(10)
<223>  Xaa10 is up to 10 positively charged amino acid residues

<400>  5

Lys Lys Ala Asp Ala Lys Ala Asp Lys Lys 
1               5                   10  


<210>  6
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is absent or a hydrophobic amino acid residue

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa2 is a negatively charged amino acid residue

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is a small hydrophobic amino acid residue

<220>
<221>  VARIANT
<222>  (4)..(4)
<223>  Xaa4 is a positively charged amino acid residue

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is a hydrophobic amino acid residue

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa6 is a negatively charged amino acid residue

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is a positively charged amino acid residue

<400>  6

Ala Asp Ala Lys Ala Asp Lys Lys 
1               5               


<210>  7
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is up to 10 positively charged amino acid residues

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa2 is a positively charged amino acid residue

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is absent or a hydrophobic amino acid residue

<220>
<221>  VARIANT
<222>  (4)..(4)
<223>  Xaa4 is a negatively charged amino acid residue

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is a small hydrophobic amino acid residue

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa6 is a positively charged amino acid residue

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is a hydrophobic amino acid residue

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  Xaa8 is a negatively charged amino acid residue

<400>  7

Lys Lys Ala Asp Ala Lys Ala Asp 
1               5               


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide

<400>  8

Arg Val Thr Val Lys Tyr Asp Arg Arg 
1               5                   


<210>  9
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is up to 10 positively charged amino acid residues

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa2 is a positively charged amino acid residues

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is a Ala or Val

<220>
<221>  VARIANT
<222>  (4)..(4)
<223>  Xaa4 is absent or Ala or 1, 2, 3 or 4 positively charged amino 
       acid residues

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa6 is a positively charged amino acid residue

<220>
<221>  VARIANT
<222>  (6)..(6)
<223>  Xaa6 is a positively charged amino acid residue

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  Xaa9 is absent or Ala or 1, 2, 3 or 4 positively charged amino 
       acid residue

<220>
<221>  VARIANT
<222>  (10)..(10)
<223>  Xaa10 is a positively charged amino acid residue

<220>
<221>  VARIANT
<222>  (12)..(12)
<223>  Xaa12 is up to 10  positively charged amino acid residues

<400>  9

Lys Lys Ala Ala Lys Tyr Gln Tyr Ala Lys Lys Lys 
1               5                   10          


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is up to 10 positively charged amino acid residues

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa2 is a positively charged amino acid residue

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is Ala or Val

<220>
<221>  VARIANT
<222>  (4)..(4)
<223>  Xaa4 is absent or Ala or 1, 2, 3, or 4 positively charged amino 
       acid resdiues

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is a positively charged amino acid resdiue

<220>
<221>  VARIANT
<222>  (5)..(5)
<223>  Xaa5 is a positively charged amino acid resdiue

<220>
<221>  VARIANT
<222>  (9)..(9)
<223>  Xaa9 is absent or Ala or 1, 2, 3, or 4 positively charged amino 
       acid resdiues

<400>  10

Lys Lys Ala Ala Lys Tyr Gln Tyr Ala 
1               5                   


<210>  11
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide


<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is Ala or Val

<220>
<221>  VARIANT
<222>  (1)..(1)
<223>  Xaa1 is Ala or Val

<220>
<221>  VARIANT
<222>  (2)..(2)
<223>  Xaa2 is absent or Ala or 1, 2, 3 or 4 positively charged amino 
       acid residues

<220>
<221>  VARIANT
<222>  (3)..(3)
<223>  Xaa3 is a  positively charged amino acid residue

<220>
<221>  VARIANT
<222>  (7)..(7)
<223>  Xaa7 is absent or Ala, or 1, 2 3, or 4 positively charged amino 
       acid residues

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  Xaa8 is a positively charged amino acid residue

<220>
<221>  VARIANT
<222>  (8)..(8)
<223>  Xaa8 is a positively charged amino acid residue

<220>
<221>  VARIANT
<222>  (10)..(10)
<223>  Xaa10 is up to 10 positively charged amino acid residues

<400>  11

Ala Ala Lys Tyr Gln Tyr Ala Lys Lys Lys 
1               5                   10  


<210>  12

<400>  12
000

<210>  13
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide

<400>  13

Arg Val Thr Val Lys Tyr Asp Arg Arg 
1               5                   


<210>  14
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide

<400>  14

Arg Arg Val Thr Val Lys Tyr Asp Arg Arg 
1               5                   10  


<210>  15
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide


<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  PHOSPHORYLATION

<400>  15

Arg Arg Val Thr Val Lys Tyr Asp Arg Arg 
1               5                   10  


<210>  16
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide

<400>  16

Arg Arg Val Thr Val Lys Tyr Lys Arg Arg 
1               5                   10  


<210>  17
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide


<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  PHOSPHORYLATION

<400>  17

Arg Arg Val Thr Val Lys Tyr Lys Arg Arg 
1               5                   10  


<210>  18
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide

<400>  18

Arg Arg Lys Thr Val Lys Tyr Asp Arg Arg 
1               5                   10  


<210>  19
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivert enhancement peptide

<400>  19

Lys Ala Lys Tyr Gln Tyr 
1               5       


<210>  20
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide

<400>  20

Arg Arg Asp Tyr Lys Val Glu Val Arg Arg 
1               5                   10  


<210>  21
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  drug delivery enhancement peptide

<400>  21

Lys Arg Arg Tyr Gln Tyr Lys Ala Lys Arg 
1               5                   10  


